Treating dyslipidemia in the high-risk patient.J Fam Pract. 2010 Feb; 59(2):E1.JF
Clinical trials demonstrate that cardiovascular event rates diminish as low-density lipoprotein (LDL)-cholesterol and apolipoprotein B-containing particles are lowered with statin treatment. The relationship between LDL-cholesterol and cardiovascular events seems to be linear, with no lowest threshold. While LDL-cholesterol remains the primary target for coronary heart disease prevention, non-HDL-cholesterol is an important secondary target in patients with mixed dyslipidemia.